“We hosted a doc call on 10/29 to discuss SEL-212. Our consultant noted some of the main potential advantages of SEL-212 vs. the standard of care including; 1) Improved treatment regimen with fewer infusions (1x/month) vs. a proposed Krystexxa combo (2x/month + daily or weekly anti-proliferative agent) and 2) Superior safety profile. Our consultant believes SEL-212 is ready for phase 3 given considerable amounts of data generated to date on treatment regimen and dosing along with clear objective measurements showing tophi mitigation and lowering of uric acid levels in a majority of patients. She argued that had the stopping rules not been as stringent in the phase 2 trial, the results may have looked better.”,” Mizuho’s analyst wrote.
Other research analysts have also issued research reports about the company. BidaskClub upgraded Selecta Biosciences from a hold rating to a buy rating in a report on Thursday, August 9th. Canaccord Genuity reiterated a buy rating and issued a $40.00 price target on shares of Selecta Biosciences in a report on Wednesday, July 11th. Stifel Nicolaus started coverage on Selecta Biosciences in a report on Friday, September 14th. They issued a buy rating and a $24.00 price target on the stock. Janney Montgomery Scott reiterated a buy rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. Finally, Zacks Investment Research upgraded Selecta Biosciences from a sell rating to a hold rating in a report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $27.40.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.08. Equities research analysts anticipate that Selecta Biosciences will post -3.07 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of Selecta Biosciences by 43.7% in the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after purchasing an additional 5,103 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Selecta Biosciences by 37.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock valued at $447,000 after purchasing an additional 9,100 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Selecta Biosciences by 1.6% in the first quarter. BlackRock Inc. now owns 629,978 shares of the company’s stock valued at $6,420,000 after purchasing an additional 9,749 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Selecta Biosciences by 27.2% in the second quarter. Bank of New York Mellon Corp now owns 47,273 shares of the company’s stock valued at $626,000 after purchasing an additional 10,114 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Selecta Biosciences by 11.9% in the second quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock valued at $2,076,000 after purchasing an additional 16,615 shares in the last quarter. Institutional investors own 48.63% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.